Skip to main content
Print Save

Generic Belrapzo Availability

Last updated on Oct 6, 2021.

Belrapzo is a brand name of bendamustine, approved by the FDA in the following formulation(s):

BELRAPZO (bendamustine hydrochloride - solution;iv (infusion))

  • Manufacturer: EAGLE PHARMS
    Approval date: May 15, 2018
    Strength(s): 100MG/4ML (25MG/ML) [RLD]

Has a generic version of Belrapzo been approved?

No. There is currently no therapeutically equivalent version of Belrapzo available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Belrapzo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Formulations of bendamustine
    Patent 10,010,533
    Issued: July 3, 2018
    Assignee(s): EAGLE PHARMACEUTICALS, INC.

    Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.

    Patent expiration dates:

    • January 28, 2031
      ✓ 
      Drug product
  • Patent 11,103,483

    Patent expiration dates:

    • January 28, 2031
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
      ✓ 
      Drug product
    • January 28, 2031
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
      ✓ 
      Drug product
  • Formulations of bendamustine
    Patent 8,609,707
    Issued: December 17, 2013
    Assignee(s): Eagle Pharmaceuticals, Inc.

    Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.

    Patent expiration dates:

    • August 11, 2031
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
      ✓ 
      Drug product
    • August 11, 2031
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
      ✓ 
      Drug product
  • Bendamustine pharmaceutical compositions
    Patent 8,791,270
    Issued: July 29, 2014
    Assignee(s): Cephalon, Inc.

    The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

    Patent expiration dates:

    • January 12, 2026
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
      ✓ 
      Drug product
    • January 12, 2026
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
      ✓ 
      Drug product
  • Formulations of bendamustine
    Patent 9,265,831
    Issued: February 23, 2016
    Assignee(s): Eagle Pharmaceuticals, Inc.

    Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.

    Patent expiration dates:

    • January 28, 2031
      ✓ 
      Drug product
  • Formulations of bendamustine
    Patent 9,572,796
    Issued: February 21, 2017
    Assignee(s): EAGLE PHARMACEUTICALS, INC.

    Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.

    Patent expiration dates:

    • January 28, 2031
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
      ✓ 
      Drug product
    • January 28, 2031
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
      ✓ 
      Drug product
  • Formulations of bendamustine
    Patent 9,572,797
    Issued: February 21, 2017
    Assignee(s): EAGLE PHARMACEUTICALS, INC.

    Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.

    Patent expiration dates:

    • January 28, 2031
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
    • January 28, 2031
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer